Form 4: Odyssey Therapeutics Executive Receives Stock Options

Natalie Dales, Chief of Research Operations and Portfolio Strategy at Odyssey Therapeutics, was granted 79,773 stock options.

Summary

• Natalie Dales, Chief of Research Operations and Portfolio Strategy, was granted 79,773 stock options on May 7, 2026.
• The options have an exercise price of $18.00 per share.
• The options are set to expire on May 6, 2036.
• Vesting occurs in 48 equal monthly installments starting June 7, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation with no immediate impact on company fundamentals.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Granting of stock options results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon the reporting person's continued service to the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an equity grant to an executive.

Management Comments

• The filing includes no narrative comments from management.

Industry Context

StockSavvy.ai notes that equity grants for key executives in the biotechnology sector are standard practice to incentivize long-term research and development milestones.

Comparison to Industry Standards

• The 48-month vesting schedule is consistent with standard industry practices for executive retention in the life sciences sector.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of the first installment of options on June 7, 2026.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, Form 4, Insider Trading, Stock Options, Executive Compensation